NEW YORK (360Dx) – NX Prenatal said today it has entered a strategic collaboration with Milu Labs to commercialize its test in Asia for the risk of preterm birth.
Milu will help launch the NX Prenatal test in countries including China as it pursues efforts to develop a diagnostics business in Asia focused on maternal fetal medicine and women's health.
"Given China's vast population, its healthcare system wisely focuses on disease prevention and investing in early disease detection. These efforts will minimize the costs from outcomes such as preterm birth, which can bring a lifetime of medical complications," Daniel Chai, cofounder and CEO of Milu Labs, said in a statement. "NX Prenatal's proprietary NeXosome liquid biopsy platform, together with sophisticated AI and bioinformatics/statistical approaches, has yielded the necessary breakthrough in this field – a blood test as early as 10-12 weeks which can stratify women at risk for preterm birth."
"NX Prenatal is pleased to partner with the preeminent experts at Milu," said Brian Brohman, CEO of NX Prenatal. "Their team uniquely understands the clinical, regulatory, and commercial requirements in that region for the successful launch and delivery of our novel test to patients and physicians."
Financial and other terms of the agreement were not disclosed.